Analysts Anticipate UroGen Pharma Ltd. (NASDAQ:URGN) Will Post Quarterly Sales of $17.20 Million

Wall Street brokerages expect UroGen Pharma Ltd. (NASDAQ:URGN) to announce $17.20 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for UroGen Pharma’s earnings, with the highest sales estimate coming in at $17.90 million and the lowest estimate coming in at $16.50 million. UroGen Pharma posted sales of $7.97 million in the same quarter last year, which suggests a positive year over year growth rate of 115.8%. The firm is expected to report its next quarterly earnings report on Thursday, March 17th.

On average, analysts expect that UroGen Pharma will report full year sales of $47.60 million for the current financial year, with estimates ranging from $46.90 million to $48.30 million. For the next financial year, analysts expect that the business will report sales of $108.23 million, with estimates ranging from $104.10 million to $114.50 million. Zacks’ sales averages are an average based on a survey of analysts that cover UroGen Pharma.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Monday, November 15th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.26) by ($0.09). The business had revenue of $11.35 million for the quarter, compared to the consensus estimate of $15.90 million. UroGen Pharma had a negative return on equity of 173.25% and a negative net margin of 283.41%. During the same quarter last year, the company earned ($1.31) earnings per share.

Separately, Zacks Investment Research upgraded UroGen Pharma from a “sell” rating to a “hold” rating in a research report on Friday, November 19th.

In other news, CFO Molly Henderson sold 2,587 shares of UroGen Pharma stock in a transaction that occurred on Tuesday, November 30th. The shares were sold at an average price of $12.03, for a total value of $31,121.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Elizabeth A. Barrett sold 46,968 shares of the business’s stock in a transaction that occurred on Tuesday, January 4th. The shares were sold at an average price of $9.15, for a total transaction of $429,757.20. The disclosure for this sale can be found here. Insiders sold a total of 53,723 shares of company stock worth $512,802 in the last three months. Company insiders own 12.80% of the company’s stock.

Several institutional investors have recently modified their holdings of URGN. RTW Investments LP bought a new stake in shares of UroGen Pharma in the third quarter worth $14,423,000. Great Point Partners LLC bought a new position in shares of UroGen Pharma during the 3rd quarter worth about $12,615,000. Zeke Capital Advisors LLC boosted its position in shares of UroGen Pharma by 39.8% during the 2nd quarter. Zeke Capital Advisors LLC now owns 722,875 shares of the company’s stock worth $11,038,000 after purchasing an additional 205,769 shares in the last quarter. HealthInvest Partners AB bought a new position in shares of UroGen Pharma during the 3rd quarter worth about $1,262,000. Finally, Morgan Stanley raised its holdings in shares of UroGen Pharma by 5,869.2% in the 2nd quarter. Morgan Stanley now owns 73,600 shares of the company’s stock worth $1,125,000 after acquiring an additional 72,367 shares during the last quarter.

Shares of NASDAQ:URGN traded up $0.14 during midday trading on Friday, hitting $8.49. The company had a trading volume of 95,456 shares, compared to its average volume of 137,296. UroGen Pharma has a 12 month low of $8.06 and a 12 month high of $28.20. The firm has a fifty day simple moving average of $11.59 and a 200 day simple moving average of $14.58.

UroGen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.

Featured Story: Stock Market News Sentiment

Get a free copy of the Zacks research report on UroGen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.